{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:44:44Z","timestamp":1791215084738,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA151652"],"award-info":[{"award-number":["CA151652"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA157738"],"award-info":[{"award-number":["CA157738"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.biomaterials.2014.04.015","type":"journal-article","created":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T19:45:13Z","timestamp":1398714313000},"page":"6026-6036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tetraspecific ligand for tumor-targeted delivery of nanomaterials"],"prefix":"10.1016","volume":"35","author":[{"given":"Dongwook","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2014.04.015_bib1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.addr.2012.05.004","article-title":"Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules","volume":"65","author":"Vigderman","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib3","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.2174\/13816128113199990375","article-title":"The smart targeting of nanoparticle","volume":"19","author":"Friedman","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-040210-162544","article-title":"Nanoparticle delivery of cancer drugs","volume":"63","author":"Wang","year":"2012","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib6","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib7","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analysis","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4161\/mabs.3.3.15188","article-title":"A\u00a0stable IgG like bispecific antibody targeting the epidemal growth factor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity","volume":"3","author":"Dong","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib9","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1126\/science.1165480","article-title":"Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site","volume":"323","author":"Bostrom","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1126\/science.1241145","article-title":"Antibody therapeutics in cancer","volume":"341","author":"Sliwkowski","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","article-title":"Dual targeting strategies with bispecific antibodies","volume":"4","author":"Kontermann","year":"2012","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.biomaterials.2014.04.015_bib12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4161\/mabs.23043","article-title":"Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides","volume":"5","author":"LaFleur","year":"2013","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.biomaterials.2014.04.015_bib13","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1158\/1078-0432.CCR-09-3182","article-title":"Targeting multiple kinase pathways: a change in paradigm","volume":"16","author":"Gossage","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrc3559","article-title":"Targeting the ERBB family in cancer: couples therapy","volume":"13","author":"Tebbutt","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib15","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1158\/1078-0432.CCR-07-1107","article-title":"Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy","volume":"13","author":"Youssoufian","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib16","first-page":"83","article-title":"Vascular integrins: therapeutic and imaging targets of tumor angiogenesis","author":"Curzio","year":"2010","journal-title":"Angiogenes Inhib"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib17","doi-asserted-by":"crossref","first-page":"e43077","DOI":"10.1371\/journal.pone.0043077","article-title":"Heptameric targeting ligands against EGFR and HER2 with high stability and avidity","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.yexcr.2010.01.009","article-title":"Mechanisms of resistance to HER family targeting antibodies","volume":"316","author":"Kruser","year":"2010","journal-title":"Exp Cell Res"},{"issue":"4","key":"10.1016\/j.biomaterials.2014.04.015_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1517\/14656566.2011.525218","article-title":"Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?","volume":"12","author":"Geuna","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1067\/msy.2003.32","article-title":"Prognostic value of the combination of epidermal growth factor and c-erB-2 in breast cancer","volume":"133","author":"Tsutsui","year":"2003","journal-title":"Surgery"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib21","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1038\/onc.2009.199","article-title":"Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer","volume":"28","author":"Hirsch","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ceb.2011.03.014","article-title":"The role of \u03b23-integrins in tumor angiogenesis: context is everything","volume":"23","author":"Robinson","year":"2011","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10456-009-9141-9","article-title":"Cooperation between integrin \u03b1V\u03b23 and VEGFR2 in angiogenesis","volume":"12","author":"Somanath","year":"2009","journal-title":"Angiogenesis"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00441-009-0857-z","article-title":"Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes","volume":"339","author":"Ivaska","year":"2010","journal-title":"Cell Tissue Res"},{"issue":"20","key":"10.1016\/j.biomaterials.2014.04.015_bib25","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1158\/1078-0432.CCR-11-1607","article-title":"EGFR- and VEGFR-targeted small molecule show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies","volume":"17","author":"Poindessous","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/protein\/gzq097","article-title":"Adnectins: engineered target-binding protein therapeutics","volume":"24","author":"Lipovsek","year":"2011","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nbt0897-772","article-title":"Binding proteins selected from combinational libraries of an alpha-helical bacterial receptor domain","author":"Nord","year":"1997","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.chembiol.2005.12.009","article-title":"Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in\u00a0vitro","volume":"13","author":"Getmanova","year":"2006","journal-title":"Chem Biol"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib29","doi-asserted-by":"crossref","first-page":"12656","DOI":"10.1021\/bi701215e","article-title":"Fibronectin type III domain based monobody with high avidity","author":"Duan","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib30","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jmb.2007.12.060","article-title":"Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor binding affibody molecule","volume":"376","author":"Friedman","year":"2008","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib31","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor imaging using a picomolar affinity HER2 binding affibody molecule","volume":"66","author":"Orlova","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib32","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib33","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1039\/c3an36828a","article-title":"Label-free methods of reporting biomolecular interactions by optical biosensors","volume":"138","author":"Citartan","year":"2013","journal-title":"Analyst"},{"issue":"32","key":"10.1016\/j.biomaterials.2014.04.015_bib34","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1021\/bi4009209","article-title":"The E3 ubiquitin ligase CHIP and the molecular chaperone Hsc70 form a dynamic, tethered complex","volume":"52","author":"Smith","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1593\/neo.10418","article-title":"Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer","volume":"12","author":"Hotz","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/17435889.2.1.125","article-title":"Hyperthermic effects of gold nanorods on tumor cells","volume":"2","author":"Huff","year":"2007","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib37","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1021\/ja057254a","article-title":"Cancer cell imaging and hotothermal therapy in the near-infrared region by using gold nanorods","author":"Huang","year":"2006","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev.bioeng.5.011303.120723","article-title":"Engineered nanomaterials for biophotonics applications: improving sensing, imaging, and therapeutics","author":"West","year":"2003","journal-title":"Annu Rev Biomed Eng"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/smll.201000134","article-title":"A\u00a0new era for cancer treatment: gold-nanoparticle-mediated thermal therapies","author":"Kennedy","year":"2011","journal-title":"Small"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib40","doi-asserted-by":"crossref","first-page":"17328","DOI":"10.1021\/ja907125t","article-title":"Nanoparticle mediated IgE receptor aggregation and signaling in RBL mast cells","author":"Huang","year":"2009","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/IJN.S10881","article-title":"Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer","volume":"5","author":"Day","year":"2010","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib42","first-page":"113","article-title":"Quantitative PET imaging of tumor integrin \u03b1V\u03b23 expression with 18F-FRGD2","volume":"47","author":"Zhang","year":"2006","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib43","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2184.2007.00455.x","article-title":"Assessment of epidermal growth factor receptor (EGFR, Erb1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines","volume":"40","author":"Rusnak","year":"2007","journal-title":"Cell Prolif"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib44","article-title":"Gold nanoparticle mediated cancer immunotherapy","author":"Almeida","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biomaterials.2014.04.015_bib45","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1021\/bc3000645","article-title":"Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2","volume":"23","author":"Ekerljung","year":"2012","journal-title":"Bioconjug Chem"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961214003895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961214003895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:59:10Z","timestamp":1758902350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961214003895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":45,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0142961214003895"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2014.04.015","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tetraspecific ligand for tumor-targeted delivery of nanomaterials","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2014.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}